KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Inovio Pharmaceuticals (INO) Return on Capital Employed (2016 - 2025)

Inovio Pharmaceuticals' Return on Capital Employed history spans 15 years, with the latest figure at 2.08% for Q2 2025.

  • For Q2 2025, Return on Capital Employed changed N/A year-over-year to 2.08%; the TTM value through Jun 2025 reached 2.08%, changed N/A, while the annual FY2024 figure was 1.05%, 39.0% down from the prior year.
  • Return on Capital Employed for Q2 2025 was 2.08% at Inovio Pharmaceuticals, down from 1.5% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 0.27% in Q1 2021 and bottomed at 2.08% in Q2 2025.
  • The 5-year median for Return on Capital Employed is 0.87% (2023), against an average of 0.91%.
  • The largest annual shift saw Return on Capital Employed increased 24bps in 2021 before it crashed -71bps in 2022.
  • A 5-year view of Return on Capital Employed shows it stood at 0.67% in 2021, then crashed by -46bps to 0.98% in 2022, then decreased by -5bps to 1.03% in 2023, then plummeted by -46bps to 1.5% in 2024, then crashed by -39bps to 2.08% in 2025.
  • Per Business Quant, the three most recent readings for INO's Return on Capital Employed are 2.08% (Q2 2025), 1.5% (Q4 2024), and 1.03% (Q4 2023).